• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sonendo Inc.

    6/4/24 6:05:04 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care
    Get the next $SONX alert in real time by email
    S-8 1 sonendo_2024_s-8_-_induc.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 4, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Sonendo, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    20-5041718

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

     

    26061 Merit Circle, Suite 102

    Laguna Hills, CA

    92653

    (Address of Principal Executive Offices)

    (Zip Code)

    Sonendo, Inc. 2023 Employment Inducement Incentive Award Plan

    (Full Title of the Plan)

    Bjarne Bergheim

    President and Chief Executive Officer

    26061 Merit Circle, Suite 102

    Laguna Hills, CA 92653

    (949) 766-3636

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

    Michael Sanders

    Anne G. Peetz

    Reed Smith LLP

    1901 Avenue of Stars, Suite 700

    Los Angeles, CA 90067-6078

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

    Sonendo, Inc. (the “Registrant”) is filing with the Securities and Exchange Commission (the “Commission”) this registration statement on Form S-8 (this “Registration Statement”) for the purpose of registering 1,000,000 shares (the “Additional Securities”) of its common stock, par value $0.001 per share (the “Common Stock”) to be issued under the Sonendo, Inc. 2023 Employment Inducement Incentive Award Plan, as amended by the Registrant’s board of directors on May 31, 2024 (the “Inducement Plan”), which Common Stock is in addition to the 750,000 shares of Common Stock already issuable under the Inducement Plan as registered on the Registrant’s Form S-8 filed on March 8, 2023 (File No. 333- 270368) (the “Prior Registration Statement”). The Inducement Plan provides for, among other things, the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents and other stock- or cash-based awards to eligible individuals.

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statement relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1.Plan Information.*

    Item 2. Registrant Information and Employee Plan Annual Information.*

    *The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this registration statement, Sonendo, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

    Item 3. Incorporation of Documents by Reference.

    The following documents previously filed by Sonendo, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

    (a)

    Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Commission on March 11, 2024;

    (b)

    Registrant’s Proxy Statement on Form DEF 14A filed with the Commission on April 29, 2024, as supplemented on April 29, 2024;

    (c)

    Registration’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Commission on May 8, 2024;

    (d)

    Registrant’s Current Reports on Form 8-K filed with the Commission on February 14, 2024, March 5, 2024, March 8, 2024 as amended on March 22, 2024, April 10, 2024, and April 15, 2024; and

    (e)

    The description of the Registrant’s Common Stock which is contained in a registration statement on 8-Afiled with the Commission on October 28, 2021 (File No. 001-40988) under the Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Registrant’s capital stock contained in Exhibit 4.11 to the Registrant’s Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, and any amendment or report filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of Common Stock offered have

     


     

    been sold or that deregisters all of such shares then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

    Reference is made under this Item 8 to the Exhibit Index included in this Registration Statement.

     

    Exhibit Index

     

     

     

    Exhibit

    Number

    Exhibit Description

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-40988) filed with the Commission on November 2, 2021)

     

     

     

    4.2

     

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-40988) filed with the Commission on November 2, 2021)

     

     

     

    4.3

     

    Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A (File No. 333-260136), filed with the Commission on October 25, 2021)

     

     

     

     

    5.1

     

    Opinion of Reed Smith LLP

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm

     

     

     

    23.2

     

    Consent of Reed Smith LLP (reference is made to Exhibit 5.1).

     

     

     

    24.1

     

    Power of Attorney (reference is made to the signature page hereto).

     

     

     

     

    99.1

     

    2023 Employment Inducement Incentive Award Plan (incorporated herein by reference to Exhibit 99.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333- 270368), filed with the Commission on March 8, 2023)

     

     

     

    99.2

     

    Amendment to 2023 Employment Inducement Incentive Award Plan

     

     

     

    99.3

     

    Form of Restricted Stock Unit Agreement pursuant to 2023 Employment Inducement Incentive Award Plan (incorporated herein by reference to Exhibit 99.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333- 270368), filed with the Commission on March 8, 2023)

     

     

     

     

    99.4

     

    Form of Stock Option Agreement pursuant to 2023 Employment Inducement Incentive Award Plan (incorporated herein by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333- 270368), filed with the Commission on March 8, 2023)

     

     

     

     

    107

     

    Filing Fee Table

     

     


     

     

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Laguna Hills, State of California, on this 4th day of June, 2024.

     

     

     

    Sonendo, Inc.

     

     

    By:

    /s/ Bjarne Bergheim

    Name:

    Bjarne Bergheim

    Title:

    President and Chief Executive Officer

    POWER OF ATTORNEY

    We, the undersigned officers and directors of Sonendo, Inc., hereby severally constitute and appoint Bjarne Bergheim and Chris Guo, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

    Name

    Title

    Date

    /s/ Bjarne Bergheim

    President, Chief Executive Officer and Director

     June 4, 2024

    Bjarne Bergheim

    (Principal Executive Officer)

    /s/ Chris Guo

    Interim Chief Financial Officer

     June 4, 2024

    Chris Guo

    (Principal Financial Officer and Accounting officer)

    /s/ Carolyn Beaver

     Director

     June 4, 2024

    Carolyn Beaver

    /s/ Olav Bergheim

     Director

     June 4, 2024

    Olav Bergheim

     

    /s/ Anthony P. Bihl III

     Director

     June 4, 2024

    Anthony P. Bihl III

     

    /s/ Raj Pudipeddi

    Director

     June 4, 2024

    Raj Pudipeddi

     

     

     

     

     

     

    /s/ Sadie Stern

     

    Director

     

     June 4, 2024

    Sadie Stern

     

     

     

     

     

     

     

     

     

     

     


    Get the next $SONX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SONX

    DatePrice TargetRatingAnalyst
    3/12/2024Buy → Hold
    Stifel
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    11/23/2021$16.00Buy
    Stifel
    11/23/2021$15.00Buy
    B of A Securities
    11/23/2021$30.00Buy
    Goldman Sachs
    11/23/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $SONX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcgaugh John P. bought $11,545 worth of shares (116,500 units at $0.10), increasing direct ownership by 47% to 363,797 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/23/24 6:05:19 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Bergheim Olav bought $49,504 worth of shares (520,000 units at $0.10) (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/17/24 2:30:11 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Pudipeddi Vamsi Mohan Raj bought $47,000 worth of shares (500,000 units at $0.09), increasing direct ownership by 27% to 2,374,498 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/14/24 5:18:33 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. VP Operations Mcgaugh John P. was granted 500,000 shares, increasing direct ownership by 142% to 852,896 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:48:44 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Bostjancic John J. was granted 600,000 shares, increasing direct ownership by 83% to 1,320,000 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:46:24 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    President and CEO Bergheim Bjarne was granted 1,600,000 shares, increasing direct ownership by 85% to 3,488,518 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:42:53 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer

    Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. "Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn," stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "John has been a significant contributor to all those improvements, and we expect he will continue to

    8/20/25 4:15:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance

    Sonendo, Inc. ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in

    8/13/25 10:50:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance

    Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights Generated $7.4 million of total revenue for the first quarter of 2025, representing 5% growth compared to the prior year period; Drove a substantial increase in gross margin to 44% for the first quarter of 2025, up 1600 basis points compared to the 28% gross margin for the prior year period; Reported a 48% year-over-year improvement in Adjusted EBITDA loss to $3.9 million for the first quarter of 2025

    6/4/25 6:30:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    SEC Filings

    View All

    SEC Form D filed by Sonendo Inc.

    D - Sonendo, Inc. (0001407973) (Filer)

    5/12/25 1:21:37 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Sonendo Inc.

    10-K - Sonendo, Inc. (0001407973) (Filer)

    3/26/25 4:06:45 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Sonendo Inc.

    EFFECT - Sonendo, Inc. (0001407973) (Filer)

    2/28/25 12:15:03 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sonendo downgraded by Stifel

    Stifel downgraded Sonendo from Buy to Hold

    3/12/24 7:33:34 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Morgan Stanley initiated coverage on Sonendo with a new price target

    Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90

    1/31/22 7:34:46 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Sonendo with a new price target

    Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00

    11/23/21 7:43:50 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Financials

    Live finance-specific insights

    View All

    Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

    11/11/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

    10/29/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

    Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

    8/7/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonendo Strengthens Leadership With Key Strategic Appointments

    John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

    6/5/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

    The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

    10/4/23 8:00:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

    Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

    9/26/23 8:00:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 4:40:34 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sonendo Inc.

    SC 13G - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 1:23:43 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    2/14/24 5:15:11 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care